Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Status:
New, Open
Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1: A ComboMATCH Treatment Trial
NCT#05554354
(See required screening study ECOG-ACRIN EAY191)
